GSK (GSK) announced headline results from the FIRST-ENGOT-OV44 phase III trial evaluating Zejula and Jemperli in first line advanced ovarian cancer. The trial met its primary endpoint of PFS demonstrating a statistically significant difference with the addition of dostarlimab to both standard of care carboplatin-paclitaxel chemotherapy and niraparib maintenance, with or without bevacizumab. Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: “As part of our focus in gynaecological cancers, we continue to evaluate the potential of this combination and look forward to sharing full results from the trial.” The company added: “The key secondary endpoint of overall survival did not meet statistical significance. Further analyses are ongoing and data will be shared with health authorities and presented at an upcoming scientific meeting. The safety and tolerability profile was generally consistent with the known safety profiles of the individual agents.”
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on GSK:
- GSK Hits Key Milestone in Ovarian Cancer Trial
- GSK’s ViiV Healthcare says the CHMP of EMA issued positive opinion for Vocabria
- GSK announces EMA granted PRIME Designation for GSK5764227
- GSK announces CHMP of the EMA recommended expanding approval of Jemperli
- GSK announces FDA granted BTD for Jemperli
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
